Ponatinib Active in CML, Ph+ Acute Lymphoblastic Leukemia
A phase 2 study shows antileukemic activity across categories of disease stage, mutation status.
Diagnosis & Disease Information
Boxed Warning for HBV Risk Added to Rituxan, Arzerra
The FDA is updating the labels for two drugs to warn about the risk for immunosupression-related hepatitis B virus reactivation.
Obinutuzumab Delays Disease Progression Longer than Rituxan in CLL
Genetech announced that its Phase 3 CLL11 study met its primary endpoint of progression-free survival in people with previously untreated chronic lymphocytic leukemia.
Celgene Discontinues Phase 3 Leukemia Trial
Celgene announced the discontinuation of Revlimid (lenalidomide) treatment in the open-label Phase 3 ORIGIN trial after observing an imbalance in the number of deaths in patients treated with lenalidomide vs. chlorambucil.
New Drug Application Submitted for Ibrutinib for Leukemia, Lymphoma
Janssen R&D and Pharmacyclics have submitted a New Drug Application to the FDA for the use of ibrutinib in previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma.
New Therapeutic Approaches Changing the Management of Chronic Lymphocytic Leukemia
Promising combination and targeted therapies are further improving survival rates for patients with CLL.
Treatment Options for Chronic Myelogenous Leukemia (CML)
This fact sheet educates patients about what causes acute chronic CML and how it can be treated.
Managing Practical Concerns in Chronic Myelogenous Leukemia (CML)
This fact sheet helps patients with acute chronic CML to sort through treatment options, manage side effects, and find financial aid.
Ibrutinib Promotes Remission in Chronic Lymphocytic Leukemia
Ibrutinib, a new drug that targets interactions with the tumor microenvironment, promotes remission in patients with relapsed chronic lymphocytic leukemia.
New PI3K-delta Inhibitor Shows Early Promise for High-risk CLL
Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.
- Loading...
Loading...
Loading... 
Loading...